Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NYSE:CTLT - Catalent Stock Price, Forecast & News

$61.57
-0.18 (-0.29 %)
(As of 01/24/2020 08:08 AM ET)
Today's Range
$61.25
Now: $61.57
$61.83
50-Day Range
$51.73
MA: $56.23
$61.75
52-Week Range
$34.92
Now: $61.57
$61.98
Volume522,355 shs
Average Volume585,352 shs
Market Capitalization$9.01 billion
P/E Ratio65.50
Dividend YieldN/A
Beta1.69
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 billion
Cash Flow$3.30 per share
Book Value$11.54 per share

Profitability

Net Income$137.40 million

Miscellaneous

Employees12,300
Market Cap$9.01 billion
Next Earnings Date2/3/2020 (Confirmed)
OptionableOptionable

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.07. The firm earned $664.70 million during the quarter, compared to the consensus estimate of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The business's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the business posted $0.28 earnings per share. View Catalent's Earnings History.

When is Catalent's next earnings date?

Catalent is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Catalent.

How can I listen to Catalent's earnings call?

Catalent will be holding an earnings conference call on Monday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for CTLT?

6 brokerages have issued 1-year price objectives for Catalent's stock. Their forecasts range from $49.00 to $64.00. On average, they expect Catalent's stock price to reach $58.67 in the next year. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for Catalent.

What is the consensus analysts' recommendation for Catalent?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Has Catalent been receiving favorable news coverage?

News coverage about CTLT stock has been trending very positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalent earned a daily sentiment score of 3.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Catalent.

Are investors shorting Catalent?

Catalent saw a drop in short interest in December. As of December 31st, there was short interest totalling 4,610,000 shares, a drop of 6.5% from the December 15th total of 4,930,000 shares. Based on an average trading volume of 651,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 3.2% of the company's shares are short sold. View Catalent's Current Options Chain.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Alibaba Group (BABA), Energy Transfer LP Unit (ET), Thermo Fisher Scientific (TMO), AbbVie (ABBV), Verizon Communications (VZ), NVIDIA (NVDA), CVS Health (CVS), AT&T (T), Pfizer (PFE) and Home Depot (HD).

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ironvine Capital Partners LLC (0.19%), Norris Perne & French LLP MI (0.14%), Global Thematic Partners LLC (0.09%), Mountain Pacific Investment Advisers Inc. ID (0.08%), Three Peaks Capital Management LLC (0.04%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, State of Alaska Department of Revenue and We Are One Seven LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Michael J Grippo, Ricardo Pravda, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

Which major investors are buying Catalent stock?

CTLT stock was purchased by a variety of institutional investors in the last quarter, including Three Peaks Capital Management LLC, Global Thematic Partners LLC, Nisa Investment Advisors LLC, McGuire Investment Group LLC, AdvisorShares Investments LLC, Mountain Pacific Investment Advisers Inc. ID, Ironvine Capital Partners LLC and Diversified Trust Co. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $61.57.

How big of a company is Catalent?

Catalent has a market capitalization of $9.01 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.

What is Catalent's official website?

The official website for Catalent is http://www.catalent.com/.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  561 (Vote Outperform)
Underperform Votes:  642 (Vote Underperform)
Total Votes:  1,203
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel